These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

970 related items for PubMed ID: 33752680

  • 41. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D, Katsimardou A, Kalogirou MS, Zografou I, Toumpourleka M, Imprialos K, Stavropoulos K, Stergiou I, Papadopoulos C, Doumas M.
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [Abstract] [Full Text] [Related]

  • 42. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
    Sajja AP, Dey AK, Guha A, Elnabawi Y, Joshi AA, Kalra A.
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):422-427. PubMed ID: 31064213
    [Abstract] [Full Text] [Related]

  • 43. Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.
    Lee YC, Dong YH, Yang WS, Wu LC, Lin JW, Chang CH.
    Front Pharmacol; 2022 Sep; 13():869804. PubMed ID: 36176438
    [Abstract] [Full Text] [Related]

  • 44. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?
    Berkovic MC, Bilic-Curcic I, Bozek T, Mahecic DH, Majanovic SK, Canecki-Varzic S, Andric J, Marusic S, Mrzljak A.
    World J Diabetes; 2020 Nov 15; 11(11):540-552. PubMed ID: 33269065
    [Abstract] [Full Text] [Related]

  • 45. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P, CVD-REAL Investigators and Study Group*.
    Circulation; 2017 Jul 18; 136(3):249-259. PubMed ID: 28522450
    [Abstract] [Full Text] [Related]

  • 46. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK, Bhatt DL, Montvida O.
    Eur Heart J; 2021 May 07; 42(18):1728-1738. PubMed ID: 33289789
    [Abstract] [Full Text] [Related]

  • 47. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, Renoux C, Suissa S, Azoulay L.
    BMJ; 2024 Apr 25; 385():e078242. PubMed ID: 38663919
    [Abstract] [Full Text] [Related]

  • 48. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.
    Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F.
    J Diabetes Res; 2024 Apr 25; 2024():8145388. PubMed ID: 39072050
    [Abstract] [Full Text] [Related]

  • 49. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
    Anson M, Henney AE, Zhao SS, Ibarburu GH, Lip GYH, Cuthbertson DJ, Nabrdalik K, Alam U.
    Diabetes Obes Metab; 2024 Jul 25; 26(7):2606-2623. PubMed ID: 38558280
    [Abstract] [Full Text] [Related]

  • 50. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
    Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, Chiang CE, Shaw JE, Cavender MA, Tangri N, Franch-Nadal J, Holl RW, Jørgensen ME, Norhammar A, Eriksson JG, Zaccardi F, Karasik A, Magliano DJ, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, CVD-REAL Investigators and Study Group.
    Cardiovasc Diabetol; 2021 Jul 31; 20(1):159. PubMed ID: 34332558
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E.
    BMJ; 2024 Jun 26; 385():e078483. PubMed ID: 38925801
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
    Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, Al-Khalidi H, Gaynor T, Kaltenbach LA, Kirk JK, Lingvay I, Magwire ML, O'Brien EC, Pak J, Pop-Busui R, Richardson CR, Reed M, Senyucel C, Webb L, McGuire DK, Granger CB.
    Circulation; 2021 Jul 06; 144(1):74-84. PubMed ID: 34228476
    [Abstract] [Full Text] [Related]

  • 58. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
    de Wit HM, Te Groen M, Rovers MM, Tack CJ.
    Br J Clin Pharmacol; 2016 Jul 06; 82(1):301-14. PubMed ID: 26935973
    [Abstract] [Full Text] [Related]

  • 59. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
    Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV.
    Diabetes Obes Metab; 2023 Jun 06; 25(6):1614-1623. PubMed ID: 36751968
    [Abstract] [Full Text] [Related]

  • 60. Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.
    Wallner M, Biber ME, Stolfo D, Sinagra G, Benson L, Dahlström U, Gudbjörnsdottir S, Cosentino F, Mol PGM, Rosano GMC, Butler J, Metra M, Lund LH, Ferrannini G, Savarese G.
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul 16; 10(4):296-306. PubMed ID: 38632048
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.